Key Points
- CEO Sanjiv Patel sold 43,168 shares on January 6 at an average price of $7.82 for a total of $337,573.76, reducing his stake by 6.13% to 661,041 shares (≈$5.17M).
- Relay trades around $8.18 with a market cap of $1.42B and reported a quarterly EPS of -$0.43, while analysts carry a consensus rating of Moderate Buy and a $17 consensus price target.
- Patel previously sold 62,073 shares on November 3 at $7.00 for about $434,511, indicating multiple insider sales in recent months.
Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CEO Sanjiv Patel sold 43,168 shares of the stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $7.82, for a total transaction of $337,573.76. Following the sale, the chief executive officer directly owned 661,041 shares in the company, valued at approximately $5,169,340.62. The trade was a 6.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Sanjiv Patel also recently made the following trade(s):
- On Monday, November 3rd, Sanjiv Patel sold 62,073 shares of Relay Therapeutics stock. The shares were sold at an average price of $7.00, for a total value of $434,511.00.
Relay Therapeutics Trading Up 0.1%
NASDAQ RLAY opened at $8.18 on Thursday. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -4.67 and a beta of 1.55. The stock has a 50-day moving average of $7.58 and a 200 day moving average of $5.49. Relay Therapeutics, Inc. has a twelve month low of $1.77 and a twelve month high of $9.04.
Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.04). Equities analysts predict that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.
Institutional Investors Weigh In On Relay Therapeutics
A number of large investors have recently modified their holdings of the business. FNY Investment Advisers LLC raised its position in shares of Relay Therapeutics by 100.0% in the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company's stock valued at $34,000 after buying an additional 5,000 shares during the last quarter. Quinn Opportunity Partners LLC acquired a new position in Relay Therapeutics during the second quarter worth about $35,000. May Hill Capital LLC purchased a new stake in Relay Therapeutics during the 2nd quarter valued at about $38,000. Focus Partners Advisor Solutions LLC acquired a new stake in Relay Therapeutics in the 2nd quarter valued at about $39,000. Finally, Quadrant Capital Group LLC raised its holdings in Relay Therapeutics by 245.1% in the 2nd quarter. Quadrant Capital Group LLC now owns 11,791 shares of the company's stock valued at $41,000 after acquiring an additional 8,374 shares during the last quarter. Hedge funds and other institutional investors own 96.98% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have weighed in on RLAY. Wells Fargo & Company upgraded shares of Relay Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $6.00 to $13.00 in a research report on Friday, December 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Relay Therapeutics in a research note on Tuesday, October 14th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $17.00.
View Our Latest Report on Relay Therapeutics
About Relay Therapeutics
(
Get Free Report)
Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.
The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
